Antenatal Corticosteroids to Improve Neonatal Outcomes

<table>
<thead>
<tr>
<th>Document Type</th>
<th>Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Function</td>
<td>Clinical Practice, Patient Care</td>
</tr>
<tr>
<td>Directorate(s)</td>
<td>Women’s Health</td>
</tr>
<tr>
<td>Department(s) affected</td>
<td>Maternity</td>
</tr>
<tr>
<td>Applicable for which patients, clients or residents?</td>
<td>All Auckland DHB antenatal patients</td>
</tr>
<tr>
<td>Applicable for which staff members?</td>
<td>Auckland DHB clinicians and NWH access holders</td>
</tr>
<tr>
<td>Key words (not part of title)</td>
<td>Premature birth, fFN, fetal fibronectin, tocolysis, nifedipine, magnesium sulphate, corticosteroids, delayed cord clamping, preterm labour, preterm birth, PPROM</td>
</tr>
<tr>
<td>Author – role only</td>
<td>Service Clinical Director - Secondary Maternity</td>
</tr>
<tr>
<td>Owner (see ownership structure)</td>
<td>Service Clinical Director - Secondary Maternity</td>
</tr>
<tr>
<td>Edited by</td>
<td>Clinical Policy Facilitator</td>
</tr>
<tr>
<td>Date first published</td>
<td>Yet to be determined</td>
</tr>
<tr>
<td>Date this version published</td>
<td>25 February 2017 – updated</td>
</tr>
<tr>
<td>Review frequency</td>
<td>3 yearly</td>
</tr>
<tr>
<td>Unique Identifier</td>
<td>NMP200/SSM/078</td>
</tr>
</tbody>
</table>

Contents

1. Purpose of guideline
2. Background
3. Definitions
4. Summary of guidelines
   A. In a woman at risk of early preterm birth use a single course of antenatal corticosteroids
   B. Type and amount of corticosteroid to use for single course
   C. Use repeat antenatal corticosteroids in women still at risk of early preterm, imminent birth following a single course of antenatal corticosteroids
   D. Type and amount of corticosteroid to use for repeat dose
   E. Other indications and considerations for antenatal corticosteroid use (best practice points) prior to elective caesarean section (CS)
5. Flowchart: Women at risk
6. Supporting evidence
7. Associated Auckland DHB documents
8. Disclaimer
9. Corrections and amendments
1. Purpose of guideline

To provide recommendations for the use of antenatal corticosteroids in women prior to birth to improve neonatal outcomes.

2. Background

Maternal administration of a single course of intramuscular corticosteroids prior to preterm birth has a major role in reducing mortality and major morbidity (respiratory distress syndrome, intraventricular haemorrhage and necrotising enterocolitis) in babies born prematurely and is now considered the standard of care for women at high risk of early birth (Crowley, 1990). Recent evidence from a meta-analysis assessing the use of repeat corticosteroids, demonstrates neonatal benefit from repeat dose(s) of corticosteroids to women at on-going risk of preterm birth greater than seven days (and less than 14 days) after the initial course of corticosteroids, with no evidence of adverse effect in follow-up studies of children up to school age (Crowther, 2011; McKinlay 2015).

The evidence lacks clarity regarding the best type, dose, frequency and mode of administration of corticosteroid. There is no evidence of benefit for routes of administration other than intramuscular. Many have extended the use of corticosteroids in attempt to improve neonatal outcomes for other groups eg prior to elective caesarean section after 35 weeks, women with diabetes and women with multiple pregnancy. In 2015 the Antenatal Corticosteroids given to Women Prior to Birth to Improve Fetal, Infant, Child and Adult Health: Clinical Practice Guidelines were released. These bi-national guidelines were developed by a multidisciplinary clinical practice guideline panel including several Auckland DHB representatives with all relevant data systematically reviewed and considered. The extensive guideline document provides the best evidence-based recommendations to guide decision-making in clinical practice also highlighting areas of uncertainty requiring further research.

National Women’s Health has elected to follow these guidelines for all antenatal corticosteroid use. The full document can be accessed at: [http://www.ligginstrials.org/ANC_CPG/](http://www.ligginstrials.org/ANC_CPG/)

This document provides a summary of the guidelines highlighting practice points of interest. This document should be read in conjunction with:

- **Preterm Labour (PTL) - Management of Threatened and Active PTL** guideline (see associated Auckland documents) for women at risk of spontaneous preterm birth and
- **Magnesium Sulphate for Pre-eclampsia and for Neuroprotection in Pre-Term Births <30 weeks** for women at risk of delivery ≤30 weeks gestation

3. Definitions

<table>
<thead>
<tr>
<th>Dose</th>
<th>Refers to a quantity of medicine taken at a specific time point</th>
</tr>
</thead>
<tbody>
<tr>
<td>Course</td>
<td>Refers to a series of doses administered over a designated period. In the context of corticosteroid administration the first course includes two doses given 24 (or 12 hours apart).</td>
</tr>
</tbody>
</table>
4. Summary of guidelines

Assessment of the evidence reviewed to provide strength of recommendations for these guidelines included the NHMRC and GRADE (Grading of Recommendations Assessment, Development and Evaluation) systems for guideline review.

Sections A-D below are based on NHMRC level ‘A’ and GRADE level ‘STRONG’ evidence. Section E provides direction on best practice points (currently there is insufficient evidence to make stronger recommendations).

A. In a woman at risk of early preterm birth, use a two dose course of antenatal corticosteroids:
   • When gestational age is ≤ 34+6 weeks
   • When preterm birth is planned or expected within the next seven days, even if birth is likely within 24 hours
   • Regardless of the reason the woman is considered at risk of preterm birth

Practice points of interest:
   • There is some benefit even if given <24 hours before delivery
   • Effect on perinatal mortality is if delivery occurs within next 48 hours (no effect on mortality if >48 hours but <7 days)
   • There is no benefit if delivery occurs >7 days (respiratory distress syndrome or mortality) after first course
   • Use adjunct prediction tests to identify those most likely to deliver in 48 hours/next seven days (eg for spontaneous preterm labour use fetal fibronectin or transvaginal cervical length, refer to Preterm Labour (PTL) - Management of Threatened and Active PTL guideline in associated Auckland DHB documents

B. Type and amount of corticosteroid to use for two dose course:
   • Total amount: Betamethasone 24 mg in divided doses, 24 hours apart
   • In practical terms = Celestone® two intramuscular doses of 11.4 mg, 24 hours apart
   • The following should be charted on the ONCE only section of the medication chart:

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Form</th>
<th>Dose</th>
<th>Route</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Betamethasone sodium phosphate and betamethasone acetate</td>
<td>5.7mg betamethasone per 1mL injection</td>
<td>11.4mg (2mL)</td>
<td>IM</td>
<td>A total of two doses 24 hours apart</td>
</tr>
<tr>
<td>Celestone Chronodose®</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes - In practical terms 5.7 mg Celestone Chronodose® = 6 mg betamethasone

Practice points of interest:
   • There is no clear evidence on best interval for divided doses of single course from 12 to 36 hours
   • A 12-hour interval may be considered, however, there is no evidence to suggest that if planning 24-hour interval but delivery sooner appears imminent that earlier administration of second dose will improve outcome
   • Dexamethasone is a valid alternative if betamethasone is not available. If using Dexamethasone it should be given as 24 mg in divided doses completed between 24
and 40 hours. In practical terms = dexamethasone phosphate intramuscularly, in four doses of 6 mg, 12 hours apart

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Form</th>
<th>Dose</th>
<th>Route</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dexamethasone phosphate</td>
<td>4mg dexamethasone per 1mL injection</td>
<td>6mg (1.5mL)</td>
<td>IM</td>
<td>A total of four doses, 12 hours apart</td>
</tr>
</tbody>
</table>

Notes - Dexamethasone is considered a valid alternative if betamethasone is not available. This is an unlicensed indication

C. **Use repeat antenatal corticosteroids in women still at risk of early preterm, imminent birth following an initial two dose course or single dose repeat of antenatal corticosteroids:**
   - When gestational age is ≤ 32+6 weeks
   - When at least seven days since previous dose of antenatal corticosteroids was administered
   - When preterm birth is planned or expected within the next seven days, even if birth is likely within 24 hours
   - Regardless of the reason, the woman is considered at risk of preterm birth

**Practice points of interest:**
   - Repeat corticosteroids should not be administered just because a woman who has received a first course remains undelivered. Clinical review *must* occur to assess whether she is *still* at risk of preterm birth within the next seven days
   - Use adjunct prediction tests to identify those most likely to deliver within the next seven days (e.g., for spontaneous preterm labour use fetal fibronectin or transvaginal cervical length, refer to Preterm Labour (PTL) - Management of Threatened and Active PTL guideline in associated Auckland DHB documents

D. **Type and amount of corticosteroid to use for repeat dose:**
   - Use a single repeat betamethasone dose
   - In practical terms = Celestone® intramuscular dose of 11.4 mg
   - After this dose if a patient has still not given birth ≥7 days and <14 days from previous repeat dose and is *still* considered to be at risk of preterm birth within the next seven days, a further single repeat dose of betamethasone (Celestone® 11.4mg i.m.) can be administered
   - Up to a total of three single repeat doses can be given

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Form</th>
<th>Dose</th>
<th>Route</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Betamethasone sodium phosphate and betamethasone acetate</td>
<td>5.7mg betamethasone per 1mL injection</td>
<td>11.4mg (2mL)</td>
<td>IM</td>
<td>Single dose only</td>
</tr>
</tbody>
</table>

Note - In practical terms 5.7mg Celestone Chronodose® = 6 mg betamethasone

**Practice points of interest:**
   - A single repeat course can be considered (betamethasone 24 mg in divided doses, 24 hours apart), but only be given as a single repeat, no further repeat courses or doses should be administered. This may be considered with representation and when risk of
imminent delivery is high but >7 days have already elapsed since first two dose course was given.

E. **Other indications and considerations for antenatal corticosteroid use (best practice points) prior to elective caesarean section (CS):**

**Prior to elective caesarean section (CS):**
- Where possible plan for CS ≥39+0 weeks gestation
- If is ≤ 34+6 weeks gestation give a single course of corticosteroids 48 hours prior to planned birth
- If it is ≥35+0 weeks gestation there is insufficient evidence to support standard use of corticosteroids. (If there is known lung immaturity it may be considered as a single course of corticosteroids 48 hours prior to planned birth)

**In women with diabetes in pregnancy including gestational diabetes:**
- Single course and repeat doses of corticosteroids should be given to patients at risk of preterm birth as per guidelines for general use
- Patients with diabetes receiving corticosteroids will require blood glucose monitoring and management of any subsequent hyperglycaemia. This should be done in consultation with Obstetric Physician service
- Patients with diabetes receiving corticosteroids should be monitored for puerperal sepsis
- There is insufficient evidence to support use of corticosteroids in patients with diabetes greater ≥35+0 weeks gestation, regardless of mode of delivery

**In women with multiple pregnancy:**
- Single course and repeat doses of corticosteroids should be given to patients at risk of preterm birth as per guidelines for general use
- Do not use single course and repeat doses of corticosteroids in women with a multiple pregnancy where there is no other identified risk of preterm birth
- Use adjunct prediction tests to identify those most likely to deliver in 48 hours/next seven days (eg for spontaneous preterm labour use fetal fibronectin or transvaginal cervical length, refer to Preterm Labour (PTL) - Management of Threatened and Active PTL guideline in associated Auckland DHB documents

**At gestational age 23+0 – 23+6 weeks:**
- Single course of corticosteroids should be considered in women when preterm birth is planned or expected within the next seven days, even if birth is likely within 24 hours, only once a full review has been made and if a plan has been made for ‘active intervention’ (Refer to section 12 (Threatened and active PTL at <24+0 weeks) in the Preterm Labour (PTL) - Management of Threatened and Active PTL guideline in associated Auckland DHB documents
5. Flowchart: Women at risk

Woman at risk of preterm birth 24+0 to 34 weeks + 6 days gestation

Give two doses of **Celestone Chronodose®** 11.4 mg IM 24 hours apart

Woman still at risk of PTB 7 days from initial dose of **Celestone Chronodose®** and < 32+6 week’s gestation?

- **YES**
  - Single dose of 11.4mg Celestone IM (maximum 3 repeat doses in total)

- **NO**
  - Stop

*If printed, this document is only valid for the day of printing.*
6. Supporting evidence


7. Associated Auckland DHB documents

- [Diabetes in Pregnancy](http://example.com)
- [Fetal Surveillance Policy](http://example.com)
- [Group B Streptococcus (GBS) – prevention of early – Onset Neonatal Infection](http://example.com)
- [Intrapartum Care – Normal Labour and Birth](http://example.com)
- [Magnesium Sulphate for Pre-eclampsia & for Neuroprotection in Pre-Term Births <30 weeks](http://example.com)
- [Preterm Labour (PTL) - Management of Threatened and Active PTL guideline](http://example.com)
- [Point of Care Testing Equipment Management – POCT Protocol](http://example.com)
- [Rupture of Membranes in Pregnancy](http://example.com)

8. Disclaimer

No guideline can cover all the variations required for specific circumstances. It is the responsibility of the health care practitioners using this Auckland DHB guideline to adapt it for safe use within their own institution, recognise the need for specialist help, and call for it without delay, when an individual patient falls outside of the boundaries of this guideline.

9. Corrections and amendments

The next scheduled review of this document is as per the document classification table (page 1). However, if the reader notices any errors or believes that the document should be reviewed before the scheduled date, they should contact the owner or the [Clinical Policy Facilitator](http://example.com) without delay.